IpiNovyx Bio
Developing multiple series of highly selective, ultra potent small molecule therapeutics for the treatment of autoimmune and inflammatory disorders.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
* | $10.0m | Seed | |
| Total Funding | 000k | ||
Related Content
IpiNovyx Bio is a biopharmaceutical company that is developing a platform of immunoproteasome-modulating therapeutics to treat autoimmune and inflammatory diseases. The company's drug development candidates are based on its proprietary technology platform, which allows for the creation of highly-selective and potent small molecule therapeutics.
IpiNovyx Bio's lead compounds are highly selective for the immunoproteasome, which is a type of proteasome that is involved in the immune system. This selectivity allows the company's drugs to target the immune system without affecting other parts of the body. The company is developing its drugs for the treatment of a variety of autoimmune and inflammatory diseases, including lupus, rheumatoid arthritis, and multiple sclerosis.
The company has raised $10 million in seed financing from a syndicate of investors that includes Viva BioInnovator, Eli Lilly and Company, and HSS. The company is using this funding to advance its lead drug candidates toward first-in-human clinical studies.
Keywords: biopharmaceutical, immunoproteasome, autoimmune diseases, inflammatory diseases, small molecule therapeutics, drug development, seed financing, clinical studies, selective inhibition, proteasome inhibitors